首页> 外文期刊>Journal of enzyme inhibition and medicinal chemistry. >Design, synthesis, and pharmacological evaluation of 2-amino-5-nitrothiazole derived semicarbazones as dual inhibitors of monoamine oxidase and cholinesterase: effect of the size of aryl binding site
【24h】

Design, synthesis, and pharmacological evaluation of 2-amino-5-nitrothiazole derived semicarbazones as dual inhibitors of monoamine oxidase and cholinesterase: effect of the size of aryl binding site

机译:设计,合成和药理学评估的2-氨基-5-硝基噻唑衍生的半咔唑酮作为单胺氧化酶和胆碱酯酶的双重抑制剂:芳基结合位点大小的影响

获取原文
       

摘要

Abstract A series of 2-amino-5-nitrothiazole derived semicarbazones were designed, synthesised and investigated for MAO and ChE inhibition properties. Most of the compounds showed preferential inhibition towards MAO-B. Compound 4 , (1-(1-(4-Bromophenyl)ethylidene)-4-(5-nitrothiazol-2-yl)semicarbazide) emerged as lead candidate (IC50?=?0.212?μM, SI?=?331.04) against MAO-B; whereas compounds 21 1-(5-Bromo-2-oxoindolin-3-ylidene)-4-(5-nitrothiazol-2-yl)semicarbazide (IC50?=?0.264?μM) and 17 1-((4-Chlorophenyl) (phenyl)methylene)-4-(5-nitrothiazol-2-yl)semicarbazide (IC50?=?0.024?μM) emerged as lead AChE and BuChE inhibitors respectively; with activity of compound 21 almost equivalent to tacrine. Kinetic studies indicated that compound 4 exhibited competitive and reversible MAO-B inhibition while compounds 21 and 17 showed mixed-type of AChE and BuChE inhibition respectively. Docking studies revealed that these compounds were well-accommodated within MAO-B and ChE active sites through stable hydrogen bonding and/or hydrophobic interactions. This study revealed the requirement of small heteroaryl ring at amino terminal of semicarbazone template for preferential inhibition and selectivity towards MAO-B. Our results suggest that 5-nitrothiazole derived semicarbazones could be further exploited for its multi-targeted role in development of anti-neurodegenerative agents. A library of 2-amino-5-nitrothiazole derived semicarbazones ( 4 – 21 ) was designed, synthesised and evaluated for in vitro MAO and ChE inhibitory activity. Compounds 4 , 21 and 17 (shown) have emerged as lead MAO-B (IC50:0.212?μM, competitive and reversible), AChE (IC50:0.264?μM, mixed and reversible) and BuChE (IC50:0.024?μM, mixed and reversible) inhibitor respectively. SAR studies disclosed several structural aspects significant for potency and selectivity and indicated the role of size of aryl binding site in potency and selectivity towards MAO-B. Antioxidant activity and neurotoxicity screening results further suggested their multifunctional potential for the therapy of neurodegenerative diseases.
机译:摘要设计,合成和研究了一系列2-氨基-5-硝基噻唑衍生的半咔唑类化合物对MAO和ChE的抑制作用。大多数化合物显示出对MAO-B的优先抑制。化合物4(1-(1-(4-(溴代苯基)亚乙基)-4-(5-硝基噻唑-2-基)半氨基叠氮化物)成为潜在的候选候选化合物(IC 50 ?=?0.212?μM ,SI?=?331.04)对MAO-B;而化合物21 1-(5-Bromo-2-oxoindolin-3-ylidene)-4-(5-nitrothiazol-2-yl)semicarbazide(IC 50 ?=?0.264?μM)和17 1-((4-氯苯基)(苯基)亚甲基)-4-(5-硝基噻唑-2-基)氨基脲(IC 50 ?=?0.024?μM)出现作为AChE和BuChE的先导抑制剂分别;化合物21的活性几乎等同于他克林。动力学研究表明,化合物4表现出竞争性和可逆性MAO-B抑制作用,而化合物21和17表现出混合型的AChE和BuChE抑制作用。对接研究表明,这些化合物通过稳定的氢键和/或疏水作用很好地容纳在MAO-B和ChE活性位点内。这项研究揭示了在氨基脲模板的氨基末端有小的杂芳基环对于优先抑制和对MAO-B的选择性的要求。我们的结果表明,由于5-硝基噻唑衍生的半咔唑酮在抗神经退行性药物的开发中具有多靶点作用,因此可以进一步加以利用。设计,合成并评估了由2-氨基-5-硝基噻唑衍生的半咔唑酮(4-21)库的体外MAO和ChE抑制活性。化合物4、21和17(如图所示)以先导MAO-B(IC 50 :0.212?M,具有竞争性和可逆性),AChE(IC 50 :0.264? μM,混合和可逆)和BuChE(IC 50 :0.024?M,混合和可逆)抑制剂。 SAR研究揭示了对效力和选择性具有重要意义的几个结构方面,并指出了芳基结合位点大小在对MAO-B的效力和选择性中的作用。抗氧化活性和神经毒性筛选结果进一步表明它们具有治疗神经变性疾病的多功能潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号